14,581 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. bought a new position in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 14,581 shares of the company’s stock, valued at approximately $79,000.

Several other institutional investors and hedge funds have also recently modified their holdings of DMAC. Susquehanna International Group LLP grew its holdings in shares of DiaMedica Therapeutics by 269.5% during the fourth quarter. Susquehanna International Group LLP now owns 374,845 shares of the company’s stock worth $2,035,000 after purchasing an additional 273,395 shares in the last quarter. 683 Capital Management LLC purchased a new position in DiaMedica Therapeutics in the 4th quarter worth approximately $413,000. Northern Trust Corp grew its stake in DiaMedica Therapeutics by 49.8% in the 4th quarter. Northern Trust Corp now owns 180,192 shares of the company’s stock worth $978,000 after buying an additional 59,902 shares in the last quarter. Jane Street Group LLC bought a new position in shares of DiaMedica Therapeutics in the 4th quarter worth $229,000. Finally, Paragon Associates & Paragon Associates II Joint Venture raised its position in shares of DiaMedica Therapeutics by 6.7% during the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 514,784 shares of the company’s stock valued at $2,795,000 after buying an additional 32,170 shares in the last quarter. Hedge funds and other institutional investors own 10.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright upped their target price on shares of DiaMedica Therapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Wednesday, March 19th.

DiaMedica Therapeutics Trading Up 1.7%

Shares of DiaMedica Therapeutics stock opened at $4.27 on Tuesday. The firm has a market capitalization of $183.11 million, a PE ratio of -7.62 and a beta of 1.29. DiaMedica Therapeutics Inc. has a 12 month low of $2.14 and a 12 month high of $6.82. The business’s 50-day moving average price is $4.10 and its 200-day moving average price is $5.00.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). During the same quarter in the prior year, the firm earned ($0.14) EPS. As a group, analysts predict that DiaMedica Therapeutics Inc. will post -0.59 earnings per share for the current fiscal year.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.